大血管闭塞急性缺血性卒中血管内再灌注后动脉内替奈普酶:POST-TNK随机临床试验
POST-TNK试验在中国34家医院纳入540例前循环大血管闭塞且血管内血栓切除术后eTICI 2c-3级再灌注、未接受静脉溶栓的患者,随机接受动脉内替奈普酶0.0625 mg/kg或不接受动脉内溶栓。90天无残疾比例分别为49.1%与44.1%(校正RR 1.15,95%CI 0.97-1.36,P=0.11),差异无统计学意义;症状性颅内出血与90天死亡均无显著差异。
要点
- 动脉内替奈普酶未显著提高90天无残疾比例(49.1% vs 44.1%,校正RR 1.15,95%CI 0.97-1.36,P=0.11)。
- 90天死亡率16.0% vs 19.3%(校正HR 0.75,95%CI 0.50-1.13,P=0.16),无显著差异。
- 症状性颅内出血6.3% vs 4.4%(校正RR 1.43,95%CI 0.68-2.99,P=0.35),无显著差异。
核心结论
- 对于大血管闭塞急性缺血性卒中在最后已知良好时间24小时内接受EVT并获得近完全至完全再灌注的患者,辅助动脉内替奈普酶未显著增加90天无残疾的可能性。
研究设计与样本
- 研究者发起的随机、开放标签、盲法结局评估试验,在中国34家医院实施,纳入540例前循环大血管闭塞、EVT后eTICI 2c-3级且未接受静脉溶栓的患者。
- 招募时间为2022年10月26日至2024年3月1日,最终随访时间为2024年6月3日,共539例(99.8%)完成试验(中位年龄69岁,女性221例[40.9%])。
主要发现
- 90天mRS 0-1分比例在动脉内替奈普酶组为49.1%(132/269),对照组为44.1%(119/270),校正RR 1.15(95%CI 0.97-1.36),P=0.11。
- 90天死亡率在动脉内替奈普酶组为16.0%,对照组为19.3%,校正HR 0.75(95%CI 0.50-1.13),P=0.16。
- 症状性颅内出血比例在动脉内替奈普酶组为6.3%,对照组为4.4%,校正RR 1.43(95%CI 0.68-2.99),P=0.35。
关键数值与推荐
- 入组标准为最后已知良好时间24小时内的前循环大血管闭塞、EVT后eTICI 2c-3级再灌注且未接受静脉溶栓。
- 干预为动脉内替奈普酶0.0625 mg/kg(n=269),对照为不接受动脉内溶栓(n=271)。
- 主要疗效终点为90天mRS 0-1分,主要安全终点为90天死亡和48小时内症状性颅内出血。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The impact of adjunctive intra-arterial tenecteplase administration following near-complete to complete reperfusion by endovascular thrombectomy (EVT) for acute ischemic stroke is unknown. OBJECTIVE: To assess the efficacy and adverse events of adjunctive intra-arterial tenecteplase in patients with large vessel occlusion stroke who had achieved near-complete to complete reperfusion (defined as a score on the expanded Thrombolysis in Cerebral Infarction [eTICI] scale of 2c to 3) after EVT. DESIGN, SETTING, AND PARTICIPANTS: Investigator-initiated, randomized, open-label, blinded outcome assessment trial implemented at 34 hospitals in China among 540 patients with stroke due to proximal intracranial large vessel occlusion within 24 hours of the time they were last known to be well, with an eTICI score of 2c to 3 after EVT, and without prior intravenous thrombolysis. Recruitment took place between October 26, 2022, and March 1, 2024, with final follow-up on June 3, 2024. INTERVENTIONS: Eligible patients were randomly assigned to receive intra-arterial tenecteplase (n = 269) at 0.0625 mg/kg or no intra-arterial thrombolysis (control group; n = 271). MAIN OUTCOMES AND MEASURES: The primary efficacy outcome was freedom from disability, defined as a score of 0 or 1 on the modified Rankin Scale (range, 0 [no symptoms] to 6 [death]) at 90 days. The primary safety outcomes were death at 90 days and symptomatic intracranial hemorrhage within 48 hours. RESULTS: A total of 539 participants (99.8%) completed the trial (median age, 69 years; 221 female [40.9%]). The proportion with a modified Rankin Scale score of 0 or 1 at 90 days was 49.1% (132/269) in the intra-arterial tenecteplase group and 44.1% (119/270) in the control group (adjusted risk ratio, 1.15 [95% CI, 0.97-1.36]; P = .11). Ninety-day mortality was 16.0% and 19.3% (adjusted hazard ratio, 0.75 [95% CI, 0.50-1.13]; P = .16), respectively. The proportions of symptomatic intracranial hemorrhage were 6.3% and 4.4% (adjusted risk ratio, 1.43 [95% CI, 0.68-2.99]; P = .35), respectively. CONCLUSIONS AND RELEVANCE: In patients with acute ischemic stroke due to large vessel occlusion presenting within 24 hours of time last known to be well and who had achieved near-complete to complete reperfusion after EVT, adjunctive intra-arterial tenecteplase did not significantly increase the likelihood of freedom from disability at 90 days. TRIAL REGISTRATION: ChiCTR.org.cn Identifier: ChiCTR2200064809.
引用
- Huang J, Yang J, Liu C, et al. Intra-Arterial Tenecteplase Following Endovascular Reperfusion for Large Vessel Occlusion Acute Ischemic Stroke: The POST-TNK Randomized Clinical Trial. JAMA. 2025. PMID: 39804681. doi:10.1001/jama.2024.23466
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。